Trusted Resource for Clinical Trials, Protocols & Progress
Results disclosure on public registries is not optional—it’s a mandated obligation governed by regulations such as FDAAA 801, EU Regulation 536/2014, and WHO best practices. Regulatory bodies like the FDA, EMA, and WHO expect timely posting of summary results to promote data transparency and uphold ethical standards for participant protection.
Click to read the full article.
Summary results tables are the foundation of data transparency on public clinical trial registries. These tables condense the trial’s key findings into structured, readable, and regulatory-compliant formats. Agencies like the FDA, EMA, and WHO require accurate tabular summaries for participant flow, baseline characteristics, outcomes, and adverse events.
Click to read the full article.
Disclosing negative or failed clinical trial outcomes is a critical part of ethical and regulatory compliance. While sponsors may hesitate to publish trials that did not meet endpoints, regulators such as the EMA, FDA, and WHO emphasize that all results—positive, negative, or inconclusive—must be made publicly available.
Click to read the full article.
Global regulations require sponsors to publicly disclose safety and efficacy endpoints of completed clinical trials. This mandate ensures scientific integrity, supports patient trust, and enhances public access to clinical evidence. The FDAAA Final Rule, EU Clinical Trial Regulation (CTR), and WHO Joint Statement are among the key regulatory frameworks enforcing this practice.
Click to read the full article.
Clinical trial result disclosure is not merely an ethical responsibility—it is a legal requirement enforced by multiple global regulations. The U.S. FDA Amendment Act (FDAAA) 801 and Final Rule, EU Clinical Trial Regulation (EU CTR), and WHO Joint Statement on Public Disclosure of Results mandate the timely posting of results in public registries like ClinicalTrials.gov and EudraCT.
Click to read the full article.
Timely posting of clinical trial results is not only a regulatory obligation but also a reflection of ethical research conduct. As per FDA, EMA, and WHO requirements, sponsors must post summary results within 12 months of the trial’s primary completion date. Missing these deadlines can lead to financial penalties, public flagging, and loss of regulatory trust. Thus, effective tools for tracking these timelines are essential to compliance.
Click to read the full article.
The Clinical Study Report (CSR) and registry result postings serve different regulatory purposes but originate from the same clinical dataset. The CSR, structured according to ICH E3 guidelines, provides detailed analysis for regulatory reviewers. Meanwhile, trial registries such as ClinicalTrials.gov and CTIS require a summarized version for public transparency.
Click to read the full article.
Accurate reporting of clinical trial results on public registries such as ClinicalTrials.gov and the EU Clinical Trials Information System (CTIS) is a regulatory and ethical obligation. However, due to differences in data structure, formatting requirements, and limited internal QC, sponsors often make avoidable mistakes. These can lead to public queries, regulatory penalties, or inspection findings.
Click to read the full article.
Regulatory agencies such as the FDA and EMA have significantly increased scrutiny of trial result disclosure practices. Sponsors are now expected not only to submit timely and accurate results but also to track their performance in doing so. Compliance metrics offer transparency, aid internal benchmarking, and support audit readiness.
Click to read the full article.
As the push for greater clinical trial transparency grows, sponsors conducting multinational studies are facing an increasingly complex challenge: complying with results disclosure requirements across jurisdictions. While the overarching goal is to improve public access and research reproducibility, divergent timelines, formats, and privacy expectations create hurdles. This tutorial explores the common issues in global results disclosure and offers proven mitigation strategies to streamline reporting and avoid non-compliance.
Click to read the full article.
